Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir

Jay S. Pepose, Cheryl L Newman, Michael C. Bach, Thomas C. Quinn, Richard F. Ambinder, Gary N. Holland, Peter S. Hodstrom, Henry M. Frey, Robert Y. Foos

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Ganciclovir is a new antiviral compound (also called BW B759U, DHPG, BIOLF-62, and 2'NDG) that has been used for the treatment of cytomegalovirus (CMV) retinopathy in immunocompromised patients (bone marrow recipients or acquired immune deficiency syndrome [AIDS] victims). The authors studied the eyes of three AIDS patients with CMV retinopathy who died while receiving ganciclovir chemotherapy. Gross, microscopic, and ultrastructural studies of these cases showed varying degrees of retinal scarring and active CMV lesions at the margins of the scars. CMV antigens were localized in cells at all layers of retina at the border of the lesions and in isolated cells in a perivascular location within histologically normal appearing retina. These areas probably represent sites of recrudescence when the drug is discontinued. In situ hybridization using a cloned complementary DNA (cDNA) probe of human CMV corroborated the immunocytologic localization of the virus. Ultrastructural studies showed megalic syncytial cells containing mostly capsids exclusively in the cell nucleus. The cytoplasmic electron-dense membrane-bound bodies that have characterized untreated cases of CMV retinopathy were absent in the treated cases. An attempt to isolate CMV in tissue culture from the vitreous and retina of one of the cases yielded a negative result. Our results indicate that ganciclovir does not effectively eliminate CMV from the retina nor does it suppress expression of all viral genes. Ganciclovir appears to function by limiting viral DNA synthesis and subsequent packaging of viral DNA into infectious units, thereby acting as a virostatic chemotherapeutic agent.

Original languageEnglish (US)
Pages (from-to)414-424
Number of pages11
JournalOphthalmology
Volume94
Issue number4
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Ganciclovir
Cytomegalovirus
Antiviral Agents
Retina
Viral DNA
Therapeutics
Cicatrix
Acquired Immunodeficiency Syndrome
Viral Genes
Capsid
DNA Probes
Immunocompromised Host
Product Packaging
Cell Nucleus
In Situ Hybridization
Complementary DNA
Bone Marrow
Electrons
Viruses
Antigens

Keywords

  • AIDS
  • BW B759U
  • DHPG
  • antivirals
  • cytomegalovirus
  • ganciclovir
  • herpesviruses
  • retinitis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Pepose, J. S., Newman, C. L., Bach, M. C., Quinn, T. C., Ambinder, R. F., Holland, G. N., ... Foos, R. Y. (1987). Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir. Ophthalmology, 94(4), 414-424. https://doi.org/10.1016/S0161-6420(87)33455-4

Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir. / Pepose, Jay S.; Newman, Cheryl L; Bach, Michael C.; Quinn, Thomas C.; Ambinder, Richard F.; Holland, Gary N.; Hodstrom, Peter S.; Frey, Henry M.; Foos, Robert Y.

In: Ophthalmology, Vol. 94, No. 4, 01.01.1987, p. 414-424.

Research output: Contribution to journalArticle

Pepose, JS, Newman, CL, Bach, MC, Quinn, TC, Ambinder, RF, Holland, GN, Hodstrom, PS, Frey, HM & Foos, RY 1987, 'Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir', Ophthalmology, vol. 94, no. 4, pp. 414-424. https://doi.org/10.1016/S0161-6420(87)33455-4
Pepose, Jay S. ; Newman, Cheryl L ; Bach, Michael C. ; Quinn, Thomas C. ; Ambinder, Richard F. ; Holland, Gary N. ; Hodstrom, Peter S. ; Frey, Henry M. ; Foos, Robert Y. / Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir. In: Ophthalmology. 1987 ; Vol. 94, No. 4. pp. 414-424.
@article{0708a171dd614a36b9434a407efebb15,
title = "Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir",
abstract = "Ganciclovir is a new antiviral compound (also called BW B759U, DHPG, BIOLF-62, and 2'NDG) that has been used for the treatment of cytomegalovirus (CMV) retinopathy in immunocompromised patients (bone marrow recipients or acquired immune deficiency syndrome [AIDS] victims). The authors studied the eyes of three AIDS patients with CMV retinopathy who died while receiving ganciclovir chemotherapy. Gross, microscopic, and ultrastructural studies of these cases showed varying degrees of retinal scarring and active CMV lesions at the margins of the scars. CMV antigens were localized in cells at all layers of retina at the border of the lesions and in isolated cells in a perivascular location within histologically normal appearing retina. These areas probably represent sites of recrudescence when the drug is discontinued. In situ hybridization using a cloned complementary DNA (cDNA) probe of human CMV corroborated the immunocytologic localization of the virus. Ultrastructural studies showed megalic syncytial cells containing mostly capsids exclusively in the cell nucleus. The cytoplasmic electron-dense membrane-bound bodies that have characterized untreated cases of CMV retinopathy were absent in the treated cases. An attempt to isolate CMV in tissue culture from the vitreous and retina of one of the cases yielded a negative result. Our results indicate that ganciclovir does not effectively eliminate CMV from the retina nor does it suppress expression of all viral genes. Ganciclovir appears to function by limiting viral DNA synthesis and subsequent packaging of viral DNA into infectious units, thereby acting as a virostatic chemotherapeutic agent.",
keywords = "AIDS, BW B759U, DHPG, antivirals, cytomegalovirus, ganciclovir, herpesviruses, retinitis",
author = "Pepose, {Jay S.} and Newman, {Cheryl L} and Bach, {Michael C.} and Quinn, {Thomas C.} and Ambinder, {Richard F.} and Holland, {Gary N.} and Hodstrom, {Peter S.} and Frey, {Henry M.} and Foos, {Robert Y.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1016/S0161-6420(87)33455-4",
language = "English (US)",
volume = "94",
pages = "414--424",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Pathologic Features of Cytomegalovirus Retinopathy after Treatment with the Antiviral Agent Ganciclovir

AU - Pepose, Jay S.

AU - Newman, Cheryl L

AU - Bach, Michael C.

AU - Quinn, Thomas C.

AU - Ambinder, Richard F.

AU - Holland, Gary N.

AU - Hodstrom, Peter S.

AU - Frey, Henry M.

AU - Foos, Robert Y.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Ganciclovir is a new antiviral compound (also called BW B759U, DHPG, BIOLF-62, and 2'NDG) that has been used for the treatment of cytomegalovirus (CMV) retinopathy in immunocompromised patients (bone marrow recipients or acquired immune deficiency syndrome [AIDS] victims). The authors studied the eyes of three AIDS patients with CMV retinopathy who died while receiving ganciclovir chemotherapy. Gross, microscopic, and ultrastructural studies of these cases showed varying degrees of retinal scarring and active CMV lesions at the margins of the scars. CMV antigens were localized in cells at all layers of retina at the border of the lesions and in isolated cells in a perivascular location within histologically normal appearing retina. These areas probably represent sites of recrudescence when the drug is discontinued. In situ hybridization using a cloned complementary DNA (cDNA) probe of human CMV corroborated the immunocytologic localization of the virus. Ultrastructural studies showed megalic syncytial cells containing mostly capsids exclusively in the cell nucleus. The cytoplasmic electron-dense membrane-bound bodies that have characterized untreated cases of CMV retinopathy were absent in the treated cases. An attempt to isolate CMV in tissue culture from the vitreous and retina of one of the cases yielded a negative result. Our results indicate that ganciclovir does not effectively eliminate CMV from the retina nor does it suppress expression of all viral genes. Ganciclovir appears to function by limiting viral DNA synthesis and subsequent packaging of viral DNA into infectious units, thereby acting as a virostatic chemotherapeutic agent.

AB - Ganciclovir is a new antiviral compound (also called BW B759U, DHPG, BIOLF-62, and 2'NDG) that has been used for the treatment of cytomegalovirus (CMV) retinopathy in immunocompromised patients (bone marrow recipients or acquired immune deficiency syndrome [AIDS] victims). The authors studied the eyes of three AIDS patients with CMV retinopathy who died while receiving ganciclovir chemotherapy. Gross, microscopic, and ultrastructural studies of these cases showed varying degrees of retinal scarring and active CMV lesions at the margins of the scars. CMV antigens were localized in cells at all layers of retina at the border of the lesions and in isolated cells in a perivascular location within histologically normal appearing retina. These areas probably represent sites of recrudescence when the drug is discontinued. In situ hybridization using a cloned complementary DNA (cDNA) probe of human CMV corroborated the immunocytologic localization of the virus. Ultrastructural studies showed megalic syncytial cells containing mostly capsids exclusively in the cell nucleus. The cytoplasmic electron-dense membrane-bound bodies that have characterized untreated cases of CMV retinopathy were absent in the treated cases. An attempt to isolate CMV in tissue culture from the vitreous and retina of one of the cases yielded a negative result. Our results indicate that ganciclovir does not effectively eliminate CMV from the retina nor does it suppress expression of all viral genes. Ganciclovir appears to function by limiting viral DNA synthesis and subsequent packaging of viral DNA into infectious units, thereby acting as a virostatic chemotherapeutic agent.

KW - AIDS

KW - BW B759U

KW - DHPG

KW - antivirals

KW - cytomegalovirus

KW - ganciclovir

KW - herpesviruses

KW - retinitis

UR - http://www.scopus.com/inward/record.url?scp=0023128233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023128233&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(87)33455-4

DO - 10.1016/S0161-6420(87)33455-4

M3 - Article

C2 - 3035452

AN - SCOPUS:0023128233

VL - 94

SP - 414

EP - 424

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -